| Literature DB >> 26923874 |
Pascal D Johann1, Serap Erkek2, Marc Zapatka3, Kornelius Kerl4, Ivo Buchhalter5, Volker Hovestadt3, David T W Jones6, Dominik Sturm1, Carl Hermann5, Maia Segura Wang7, Andrey Korshunov8, Marina Rhyzova9, Susanne Gröbner10, Sebastian Brabetz10, Lukas Chavez10, Susanne Bens11, Stefan Gröschel12, Fabian Kratochwil6, Andrea Wittmann6, Laura Sieber6, Christina Geörg12, Stefan Wolf13, Katja Beck3, Florian Oyen14, David Capper8, Peter van Sluis15, Richard Volckmann15, Jan Koster15, Rogier Versteeg15, Andreas von Deimling8, Till Milde16, Olaf Witt16, Andreas E Kulozik17, Martin Ebinger18, Tarek Shalaby19, Michael Grotzer19, David Sumerauer20, Josef Zamecnik21, Jaume Mora22, Nada Jabado23, Michael D Taylor24, Annie Huang24, Eleonora Aronica25, Anna Bertoni26, Bernhard Radlwimmer26, Torsten Pietsch27, Ulrich Schüller28, Reinhard Schneppenheim14, Paul A Northcott6, Jan O Korbel7, Reiner Siebert11, Michael C Frühwald29, Peter Lichter30, Roland Eils31, Amar Gajjar32, Martin Hasselblatt33, Stefan M Pfister1, Marcel Kool34.
Abstract
Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tumors in infants. Although the prognosis of ATRT patients is poor, some patients respond favorably to current treatments, suggesting molecular inter-tumor heterogeneity. To investigate this further, we genetically and epigenetically analyzed 192 ATRTs. Three distinct molecular subgroups of ATRTs, associated with differences in demographics, tumor location, and type of SMARCB1 alterations, were identified. Whole-genome DNA and RNA sequencing found no recurrent mutations in addition to SMARCB1 that would explain the differences between subgroups. Whole-genome bisulfite sequencing and H3K27Ac chromatin-immunoprecipitation sequencing of primary tumors, however, revealed clear differences, leading to the identification of subgroup-specific regulatory networks and potential therapeutic targets.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26923874 DOI： 10.1016/j.ccell.2016.02.001
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743